早期乳腺癌术前加速部分乳腺照射:前瞻性2期试验初步结果
这项前瞻性2期试验评估了早期浸润性导管乳腺癌患者接受术前三维适形加速部分乳腺照射(APBI)后行保乳手术的可行性。中位随访3.6年,无局部或区域失败,4例(15%)达病理完全缓解,4例3级血清肿,79%患者美容效果良好至优秀。
要点
- 术前三维适形APBI在早期乳腺癌中可行且耐受良好。
- 中位随访3.6年无局部或区域失败。
- 非消融剂量下病理完全缓解率15%,支持进一步探索。
核心结论
- 术前三维适形APBI在经选择的早期乳腺癌患者中可行且耐受良好,无局部复发报告,美容效果良好至优秀。
研究设计与样本
- 前瞻性2期试验,纳入T1-T2(<3 cm)、N0的早期浸润性导管乳腺癌患者,评估术前APBI后行保乳手术的可行性。
主要发现
- 4例(15%)根据H&E染色达到病理完全缓解。
- 出现4例3级血清肿;治疗后79%患者报告美容效果良好至优秀。
临床怎么用
- 对于经选择的早期乳腺癌患者,术前三维适形APBI可作为保乳综合治疗的一部分,但需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the feasibility of utilizing 3-dimensional conformal accelerated partial-breast irradiation (APBI) in the preoperative setting followed by standard breast-conserving therapy. PATIENTS AND METHODS: This was a prospective trial testing the feasibility of preoperative APBI followed by lumpectomy for patients with early-stage invasive ductal breast cancer. Eligible patients had T1-T2 (<3 cm), N0 tumors. Patients received 38.5 Gy in 3.85-Gy fractions delivered twice daily. Surgery was performed >21 days after radiation therapy. Adjuvant therapy was given as per standard of care. RESULTS: Twenty-seven patients completed treatment. With a median follow-up of 3.6 years (range, 0.5-5 years), there have been no local or regional failures. A complete pathologic response according to hematoxylin and eosin stains was seen in 4 patients (15%). There were 4 grade 3 seromas. Patient-reported cosmetic outcome was rated as good to excellent in 79% of patients after treatment. CONCLUSIONS: Preoperative 3-dimensional conformal radiation therapy-APBI is feasible and well tolerated in select patients with early-stage breast cancer, with no reported local recurrences and good to excellent cosmetic results. The pathologic response rates associated with this nonablative APBI dose regimen are particularly encouraging and support further exploration of this paradigm.
引用
- Nichols E, Kesmodel SB, Bellavance E, et al. Preoperative Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Preliminary Results of a Prospective, Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2016. PMID: 28244410. doi:10.1016/j.ijrobp.2016.11.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。